The identification of cancer as a genetic disease is based on the well-documented fact that somatic mutations are required to create the lethal malady. But that is not the whole story. Cancer is also an environmental disease since it takes time to develop with the involvement of numerous environmental factors. There have been many theories of carcinogenesis over the last century that provided much insight, but still fall short of completeness. The Somatic Mutation Theory specifies that cancers arise as a consequence of genetic mutations, but it does not stipulate the mechanisms involved or what else may be required. The Tissue Organization Field Theory specifies that cancers arise as the result of cell communication disruption, but it does not stipulate how this occurs, nor does it clarify what else may be required. Neither theory is independently sufficient based on today's knowledge. The existing experimental evidence clearly supports the Somatic Mutation Theory, and none refutes this theory based on the simple requirement of somatic mutation. The recently proffered Tissue Organization Field Theory has yet to be clearly demonstrated, but there is experimental evidence to lend support to this premise. The root of the problem is the terminology and the clear perception of the processes of carcinogenesis.
Get full access to this article
View all access options for this article.
References
1.
NerlichAG, RohrbachH, BachmeierB, ZinkA. Malignant tumors in two ancient populations: An approach to historical tumor epidemiology. Oncol Rep., 2006; 16:197–202.
2.
KaramanouM, DiamadisA, AndroutsosG. The first cases of cancer in antiquity. J Buon., 2008; 13:601–608.
3.
BakerS. Paradoxes in carcinogenesis should spur new avenues of research: An historical perspective. Disruptive Sci Tech., 2012; 2:100–107.
4.
RussellWO, WynneES. The viral theory of cancer: Evaluation of some recent work. Am J Med Sci., 1951; 222:485–493.
5.
StentGS. Molecular Genetics: An Introductory Narrative. San Francisco, California: W.H. Freeman and Company, 1971.
6.
ToozeJ. The Molecular Biology of Tumour Viruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1973.
7.
PierceGB, ShikesR, FinkLM. A Problem of Developmental Biology. Englewood Cliffs, New Jersey: Prentice-Hall, Inc., 1978.
8.
SorsaM. Somatic mutation theory. J Toxicol Environ Health., 1980; 6:977–982.
9.
PitotHC. Fundamentals of Oncology, 2nd. New York, NY: Mercel Dekker, Inc., 1981.
VarmusH, PaoW, PolitiKet al.Oncogenes come of age. Cold Spring Harb Symp Quant Biol., 2005; 70:1–9.
12.
StehelinD, VarmusHE, BishopJM, VogtPK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature., 1976; 260:170–173.
13.
ReddyEP, ReynoldsRK, SantosE, BarbacidM. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature., 1982; 300:149–152.
14.
BarbacidM. ras Genes. Annu Rev Biochem., 1987; 56:779–827.
15.
DuranteF. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memori eed Osservazioni di Chirugia Practica., 1874; 11:217–226.
16.
ConheimJ. Congenitales, quergestreiftes muskelsarkon der nireren. Virchows Arch, 1875; 65:64.
17.
SellS, PierceGB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest., 1994; 70:6–22.
18.
GurchotC. The trophoblast theory of cancer (John Beard, 1857–1924) revisited. Oncology., 1975; 31:310–333.
19.
HerbstAL, UlfelderH, PoskanzerDC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med., 1971; 284:878–881.
20.
HeidelbergerC. Chemical carcinogenesis. Annu Rev Biochem., 1975; 44:79–121.
21.
LoechlerEL, GreenCL, EssigmannJM. In vivo mutagenesis by O6-methylguanine built into a unique site in a viral genome. Proc Natl Acad Sci U S A., 1984; 81:6271–6275.
22.
WoodML, DizdarogluM, GajewskiE, EssigmannJM. Mechanistic studies of ionizing radiation and oxidative mutagenesis: Genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. Biochemistry., 1990; 29:7024–7032.
23.
MillerJA, MillerEC. Ultimate chemical carcinogens as reactive mutagenic electrophiles. Cold Spring Harb Conf. Cell Prolif., 1977; 4:605–628.
24.
MillerJA, MillerEC. Mechanisms of chemical carcinogenesis. Cancer., 1981; 47,5 Suppl:1055–1064Review.
25.
SingerB, EssigmannJM. Site-specific mutagenesis: Retrospective and prospective. Carcinogenesis., 1991; 12:949–955.
26.
WangD, KreutzerDA, EssigmannJM. Mutagenicity and repair of oxidative DNA damage: Insights from studies using defined lesions. Mutat Res., 1998; 400:99–115Review.
27.
WoganGN, HechtSS, FeltonJSet al.Environmental and chemical carcinogenesis. Semin Cancer Biol., 2004; 14:473–486.
28.
LoebLA, HarrisCC. Advances in chemical carcinogenesis: A historical review and prospective. Cancer Res., 2008; 68:6863–6872.
29.
ShrivastavN, LiD, EssigmannJM. Chemical biology of mutagenesis and DNA repair: Cellular responses to DNA alkylation. Carcinogenesis., 2010; 31:59–70Review.
30.
OlivierM, EelesR, HollsteinMet al.The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat., 2002; 19:607–614.
31.
GreenmanC, StephensP, SmithRet al.Patterns of somatic mutation in human cancer genomes. Nature., 2007; 446:153–158.
32.
StrattonMR, CampbellPJ, FutrealA. The cancer genome. Nature., 2009; 458:719–724.
33.
KanZ, JaiswalBS, StinsonJet al.Diverse somatic mutation patterns and pathway alterations in human cancers. Nature., 2010; 466:869–873.
BrashDE, RudolphJA, SimonJAet al.A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A., 1991; 88:10124–10128.
36.
GreenblattMS, BennettWP, HollsteinM, HarrisCC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 1994; 54:4855–4878.
37.
DenissenkoMF, PaoA, TangM, PfeiferGP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science., 1996; 274:430–432.
38.
PfeiferGP, DenissenkoMF, TangM. p53 mutations, benzo[a]pyrene and lung cancer: A reply. Mutagenesis., 1998; 13:537–538.
39.
CmarikJL, HumphreysWG, BrunerKLet al.Mutation spectrum and sequence alkylation selectivity resulting from modification of bacteriophage M13mp18 DNA with S-(2-chloroethyl)glutathione. Evidence for a role of S-(2-N7-guanyl)ethyl)glutathione as a mutagenic lesion formed from ethylene dibromide. J Biol Chem., 1992; 267:6672–6679.
40.
SotoAM, SonnenscheinCS. The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory. Bioessays., 2011; 5:332–340.
41.
HanahanD, WeinbergRA. Hallmarks of cancer. Cell., 2000; 100:57–70.
42.
HanahanD, WeinbergRA. Hallmarks of cancer: The next generation. Cell., 2011; 144:646.
43.
WeinbergRA. The Biology of Cancer. New York, NY: Garland Science, Taylor & Francis Group, LLC, 2007.
44.
Donne J (English poet; 1572–1631). “No Man Is an Island” quoted from Devotions Upon Emergent Occasions and Seuerall Steps in My SicknesMeditation XVII1624.
45.
BarJ, MoskovitsN, OrenM. Involvement of stromal p53 in tumor-stroma interactions. Semin Cell Dev Biol., 2010; 21:47–54.
46.
NogueraR, NietoOA, TadeoIet al.Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol., 2012; 27:693–705.
47.
BirkelandSA, StormHH, LammLUet al.Cancer risk after renal transplantation in Nordic countries, 1964–1986. Int J Cancer., 1995; 60:183–189.
48.
EuvrardS, KanitakisJ, ClaudyA. Skin cancers after organ transplantation. N Engl J Med., 2003; 348:1681–1691.
49.
KerkarSP, RestifoNP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res., 2012; 72:3125–3130.
50.
WilsonVL. Carcinogenesis. MeyersRA. Encyclopedia of Sustainability Science and Technology—Section: Environmental Toxicology. New York, NY: Springer Science Publisher, 2012.
51.
RobertsRA, SmithRA, SafeSet al.Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology., 2010; 276:85–94Erratum Toxicology. 2011;279:208.
52.
LonkarP, DedonPC. Reactive species and DNA damage in chronic inflammation: Reconciling chemical mechanisms and biological fates. Int J Cancer., 2011; 128:1999–2009.
53.
PonderBA. Genetics and cancer. Biochim Biophys Acta., 1980; 605:369–410Review.
54.
HansenMF, CaveneeWK. Genetics of cancer predisposition. Cancer Res., 1987; 47:5518–5527Review.
55.
WilsonVL. Detecting rare mutations associated with cancer risk. Am J Pharmacogenomics., 2001; 1:283–293Review.
56.
HitchinsMP. Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility. Adv Genet., 2010; 70:201–243.
57.
ZhangB, Beeghly-FadielA, LongJ, ZhengW. Genetic variants associated with breat-cancer risk: Comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol., 2011; 12:477–488.
58.
ChungCC, ChanockSJ. Current status of genome-wide association studies in cancer. Hum Genet., 2011; 130:59–78.
59.
SlabyO, Bienertova-VaskuJ, SvobodaM, VyzulaR. Genetic polymorphisms and microRNAs: New direction in molecular epidemiology of solid cancer. J Cell Mol Med., 2012; 16:8–21.
60.
LoebLA, BielasJH, BeckmanRA. Cancers exhibit a mutator phenotype: Clinical implications. Cancer Res., 2008; 68:3551–3557discussion 3557.
61.
ZegermanP, DiffleyJF. DNA replication as a target of the DNA damage checkpoint. DNA Repair (Amst)., 2009; 8:1077–1088.
62.
GoldsbyRE, LawrenceNA, HaysLEet al.Defective DNA polymerase-delta proofreading causes cancer susceptibility in mice. Nat Med., 2001; 7:638–639.
63.
ArmitageP, DollR. The age distribution of cancer and a multistage theory of cancer. Br J Cancer., 1954; 8:1–12.
64.
PetoR, RoeFJC, LeePNet al.Cancer and aging in mice and men. Br J Cancer., 1975; 32:411–426.
65.
HeS, NakadaD, MorrisonSJ. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol., 2009; 25:377–406.
66.
United States Cancer Statistics (USCS). 1999–2008 Cancer Incidence and Mortality Data, National Program of Cancer Registries (NPCR), Center for Disease Control and Prevention, Department of Health and Human Services, USA. http://apps.nccd.cdc.gov/uscs/index.aspx. 2012 July 21.
67.
LeeWR, PerantieDC, ClarkKBet al.Effect of mutagen induced cell lethality on the dose-response of germline mutations. Mutat Res., 2001; 37:340–344.
68.
DanC, GrygoryeyD, SandfortKet al.Marked aneuploidy and loss of multiple chromosomes are common in autosomal mutants isolated from normal mouse kidney epithelium. Genes Chromosomes Cancer., 2011; 50:239–249.
69.
FearonER, VogelsteinB. A genetic model of colorectal tumorigenesis. Cell., 1990; 61:759–767.
70.
FarberE. Reversible and irreversible lesions in processes of cancer development. IARC Sci Publ., 1980; 27:143–151.
71.
PitotHC. Environmental modifiers in carcinogenesis. IARC Sci Publ., 1982; 39:165–176.
72.
SharmaS, KellyTK, JonesPA. Epigenetics in cancer. Carcinogenesis., 2010; 31:27–36.
GravinaS, VijgJ. Epigenetic factors in aging and longevity. Pfugers Arch., 2010; 459:247–258.
75.
WilsonVL, YinX, ThompsonBet al.Oncogenic base substitution mutations in circulating leukocytes of normal individuals. Cancer Res., 2000; 60:1830–1834.
76.
TappRA, FengJ, JonesJWet al.Single base instability is promoted in vulvar lichen sclerosus. J Invest Dermatol., 2007; 127:2563–2576.
77.
SlaughterDP, SouthwickHW, SmejkalW. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer., 1953; 6:963–968.
78.
FranklinWA, GazdarAF, HaneyJet al.Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest., 100; 2133–2137.
79.
TakahashiT, HabuchiT, KakehiYet al.Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res., 1998; 58:5835–5841.
80.
ChaiH, BrownRE. Field effect in cancer–an update. Ann Clin Lab Sci., 2009; 39:331–337.
81.
CarlsonJA, MurphyM, SlominskiA, WilsonVL. Chapter 17: Skin cancer: evidence of skin field cancerization. DakuboGD. Field Cancerization: Basic Science and Clinical Applications. Hauppauge, NY: Nova Science Publishing, Inc., 2011.
